Breast cancer (BrCa) is the most frequently diagnosed cancer in women in the US (prevalence 2.6 million), poses a lifetime risk of 1 in 8, and has a death rate of ~40,000/year. About 10% of BrCa clusters in families (260,000 US women); however, >75% of heritable factors are unknown. The 'missing heritability' is thought to be, in part, due to rare inherited susceptibility variants. Our observations using a unique statewide genealogical and cancer database are consistent with this. Large high-risk pedigrees are accepted to be enriched for rare risk variants and a relevant study design to pursue them. The discovery of rare risk variants is important because they may have immediate relevance for the women carrying them. Furthermore, we hypothesize that more common, low- and moderate-risk variants will also exist in the genes identified. Hence, the identification of novel rare risk variants has the potential to provide immediate clinical impact as well as insight into susceptibility at the population-level and new directions for the field. Two major obstacles hinder rare risk variant discovery: a lack of powerful statistical methods for large pedigrees to identify genomic regions of importance; and genetic heterogeneity -both of which are especially challenging for common diseases, such as BrCa. Recently, we introduced shared genomic segment (SGS) methods which have been shown through simulation and proof-of-principle examples to have good power to identify chromosomal regions harboring rare risk variants in high-risk pedigrees. A regionally-guided strategy allows for efficient, focused sequencing and analysis efforts and strong filtering based on sharing. If, however, compelling regions cannot be identified, whole exome sequencing is a complementary strategy. Whether regional or whole exome, it is important that the cases sequenced in a pedigree share the underlying susceptibility variant/s. Membership in a high-risk pedigree certainly increases the likelihood for homogeneity; however, it is expected that other sources of heterogeneity will exist. We hypothesize that molecular tumor subtyping will be critical to identify more genetically homogeneous BrCa. Breast tumors are known to be heterogeneous in cellular and molecular make-up, and that this molecular heterogeneity can be reduced to four major tumor subtypes that have similar gene expression profiles based on 'intrinsic' gene sets. We will study 25 high-risk intrinsic-characterized BrCa pedigrees to identify rare BrCa risk variants and three follow-up cohorts (3,500 individuals) to identify lower-risk variants. Our massively-parallel sequencing efforts will follow a two-pronged approach, including regionally- guided and whole exome sequencing based on the existence of compelling shared regions. Our follow-up in independent cohorts is imperative for corroboration and to establish a broader understanding of how novel BrCa susceptibility genes more generally influence risk. In summary, we believe our research strategy is well- grounded, highly innovative and a powerful approach to identify new BrCa susceptibility variants.

Public Health Relevance

The ability to study large high-risk breast cancer pedigrees, in addition to our incorporation of novel analysis techniques and tumor subtyping, uniquely positions us to identify rare inherited BrCa susceptibility variants. The discovery of such variant could lead to the identification of additional common, low- and moderate-risk genetic factors and improved screening procedures in high-risk families and in the general population.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
4R01CA163353-05
Application #
9066589
Study Section
Cancer Genetics Study Section (CG)
Program Officer
Nelson, Stefanie A
Project Start
2012-08-01
Project End
2017-05-31
Budget Start
2016-06-01
Budget End
2017-05-31
Support Year
5
Fiscal Year
2016
Total Cost
Indirect Cost
Name
University of Utah
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
009095365
City
Salt Lake City
State
UT
Country
United States
Zip Code
84112
Waller, Rosalie G; Darlington, Todd M; Wei, Xiaomu et al. (2018) Novel pedigree analysis implicates DNA repair and chromatin remodeling in multiple myeloma risk. PLoS Genet 14:e1007111
Madsen, Michael J; Knight, Stacey; Sweeney, Carol et al. (2018) Reparameterization of PAM50 Expression Identifies Novel Breast Tumor Dimensions and Leads to Discovery of a Genome-Wide Significant Breast Cancer Locus at 12q15. Cancer Epidemiol Biomarkers Prev 27:644-652
Li, Jun; Li, Hongyan; Makunin, Igor et al. (2017) Panel sequencing of 264 candidate susceptibility genes and segregation analysis in a cohort of non-BRCA1, non-BRCA2 breast cancer families. Breast Cancer Res Treat 166:937-949
Camp, Nicola J; Lin, Wei-Yu; Bigelow, Alex et al. (2016) Discordant Haplotype Sequencing Identifies Functional Variants at the 2q33 Breast Cancer Risk Locus. Cancer Res 76:1916-25
Bradford, James R; Cox, Angela; Bernard, Philip et al. (2016) Consensus Analysis of Whole Transcriptome Profiles from Two Breast Cancer Patient Cohorts Reveals Long Non-Coding RNAs Associated with Intrinsic Subtype and the Tumour Microenvironment. PLoS One 11:e0163238
Bradford, James R; Wappett, Mark; Beran, Garry et al. (2016) Whole transcriptome profiling of patient-derived xenograft models as a tool to identify both tumor and stromal specific biomarkers. Oncotarget 7:20773-87
Thomas, Jane J; Abed, Mona; Heuberger, Julian et al. (2016) RNF4-Dependent Oncogene Activation by Protein Stabilization. Cell Rep 16:3388-3400
Demehri, Shadmehr; Cunningham, Trevor J; Manivasagam, Sindhu et al. (2016) Thymic stromal lymphopoietin blocks early stages of breast carcinogenesis. J Clin Invest 126:1458-70
Lin, Wei-Yu (see original citation for additional authors) (2015) Identification and characterization of novel associations in the CASP8/ALS2CR12 region on chromosome 2 with breast cancer risk. Hum Mol Genet 24:285-98
Lin, Wei-Yu; Brock, Ian W; Connley, Dan et al. (2013) Associations of ATR and CHEK1 single nucleotide polymorphisms with breast cancer. PLoS One 8:e68578

Showing the most recent 10 out of 11 publications